Like most companies in 2020, Dexcom (NSDQ:DXCM) faced a number of challenges brought on by COVID-19, public unrest and more. Dexcom chairman, president & CEO Kevin Sayer had to prioritize the health of his employees over all else, while also keeping patients safe and somehow managing to keep the diabetes giant rolling as a business. “Anybody who […]
COVID-19
BREAKING: BD orders for COVID-19 vaccine injection devices surpass 1 billion
Becton Dickinson (NYSE:BDX) announced today that orders have surpassed 1 billion for syringes and needles needed to deliver COVID-19 vaccines. The Franklin Lakes, N.J.–based medtech giant now has commitments from governments in countries including the United States, Australia, Belgium, Canada, Germany, Netherlands, Saudi Arabia, Spain and the United Kingdom. BD has already delivered more than 300 […]
BD is playing a crucial role delivering COVID-19 vaccines: Here’s how
Hundreds of millions of vaccine doses will require hundreds of millions of syringes from companies such as BD. As much-hoped-for COVID-19 vaccines roll out to the public, Becton Dickinson (NYSE:BDX) faces an arguably impressive challenge: The Franklin Lakes, N.J.–based medtech giant already has commitments to provide more than 800 million needles and syringes to deliver future COVID-19 […]
Teva Pharmaceuticals’ stock sinks 6.5% on Q3 results
Teva (NYSE: TEVA) reported third-quarter results today that matched analysts’ consensus forecast. The company will maintain its guidance for the rest of the year. Teva, which has dual headquarters in Israel and Parsippany, N.J., reported a loss of -$4.3 billion or -$3.97 per share on revenue of $3.9 billion for the quarter ended September 30, […]
HHS gives Vaxxas $22M to support vaccine patch tech
Vaxxas announced today that it has received a $22 million award from the Biomedical Advanced Research and Development Authority (BARDA) at U.S. HHS to support a clinical study involving the company’s vaccine-delivery patch. The money will mostly pay for a Phase 1 clinical study in which Vaxxas’ high-density micro-array patch (HD-MAP) delivering pandemic influenza vaccine […]
Ampio gains investigational drug nod for COVID-19 inhaler
Ampio recently announced that it received FDA investigational new drug designation to proceed with clinical trials of its Ampion inhaler for patients with COVID-19 respiratory distress. The company is expanding on its recent successful Phase I trial that administered the drug intravenously to COVID-19 patients. The new Phase I trial of inhaled Ampion will total […]
Report: China begins testing COVID-19 nasal spray vaccine
China has reportedly begun human testing for a COVID-19 vaccine which utilizes nasal spray instead of an injection. A report in Bloomberg cites a registration in the Chinese Clinical Trial Registry confirming that the nasal spray vaccine candidate developed by Xiamen University, Hong Kong University and Beijing Wantai Biological Pharmacy Enterprise is undergoing Phase I human testing. Get the […]
Thermo Fisher to manufacture Inovio COVID-19 vaccine candidate
Inovio Pharmaceuticals (NSDQ:INO) announced that Thermo Fisher Scientific (NYSE:TMO) will manufacture its COVID-19 vaccine candidate. Plymouth Meeting, Pa.-based Inovio said in a news release yesterday that Thermo Fisher signed a letter of intent to manufacture the INO-4800 COVID-19 vaccine candidate, joining a consortium of third-party manufacturers that aim to produce 100 million doses of Inovio’s vaccine by […]
Could Vaxxas’ tiny patches enable a better COVID-19 vaccine?
Tiny vaccine delivery patches could solve logistical challenges, but they face manufacturing hurdles. Here’s how Vaxxas is trying to overcome them. Merck (NYSE:MRK) and Vaxxas announced earlier this year that the pharmaceutical giant was using Vaxxas’ High Density Microarray Patch (HD-MAP) platform as a delivery platform for a vaccine candidate. Vaxxas did not disclose what […]
CureVac stock soars after $213.3M IPO
Shares of CureVac (NSDQ:CVAC) continue to rise after the company reportedly raised $213.3 million in its initial public offering on Friday. According to a report from MarketWatch, the Germany-based biotech outfit priced its IPO at $16 per share and sold more than 13.3 million shares to raise the $213.3 million. Currently, shares of CVAC are […]
